NCT07428967Recruiting
AV Node Ablation and CONDUCTion System Pacing for Atrial Fibrillation With Preserved Left Ventricular Function
AtrioVentricular Node Ablation and CONDUCTion System Pacing for Atrial Fibrillation With Preserved Left Ventricular Function - a Randomized Controlled Trial
Source: ClinicalTrials.gov · Last updated 24 Feb 2026
Brief summary (registry, in English)
AVA CONDUCT is a prospective, multicenter, randomized study with single blinding, comparing left bundle branch area (LBBA) pacing with right ventricular (RV) pacing following AV node ablation in terms of clinical, functional, and electrophysiological outcomes. The primary hypothesis is that pacing-induced cardiomyopathy, defined as a decrease in LVEF by 10% or more from baseline to an absolute value below 50%, occurs significantly more frequently in patients receiving RV pacing compared with LBBA pacing. Secondarily, LBBA pacing is expected to maintain comparable procedural safety while providing better cardiac function, resulting in improved quality of life and functional capacity compared with conventional RV pacing.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 86 (estimated)
- First submitted
- 6 Feb 2026
- Start date
- 1 Feb 2026
- Primary completion date
- 31 Dec 2028
- Lead sponsor
- St. Josefs-Hospital Wiesbaden GmbH
- Diseases
- Atrial fibrillation
- NCT number
- NCT07428967
What you commit to
- Study type: Interventional
- Planned participants: 86
- From 1 Feb 2026 to the primary completion date, 31 Dec 2028
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Surgical coronary revascularization (within the last 30 days) or current triple therapy after stent PCI
Other illness
- High grade (III°) left cardiac valvular disease
Lab values
- Impaired LVEF (\< 50%)
Other
- Pre-implanted pacemaker
- Contraindication for pacemaker implantation or AV node ablation (see chapter 5.3 for details)
- Body-mass-index \> 40 kg/m2
- Pregnancy
- Inability to give written informed consent
- Life expectancy \< 12 months
Who the study is looking for
- History of symptomatic AF (EHRA IIb - IV) despite guideline-indicated medical or interventional therapy
- Preserved LVEF (≥ 50%, assessed by echocardiography, Simpson's biplane method)
- AV node ablation scheduled independently of possible study participation
- Age ≥ 18 years
- Consent capacity
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Evangelisches Krankenhaus Hagen-Haspe Coordinator of this site? Confirm its status | Hagen | Germany | Not yet recruiting |
| St. Josefs-Hospital Wiesbaden GmbH Coordinator of this site? Confirm its status | Wiesbaden | Germany | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.